Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardioprotective Prophylaxis During Intensive Chemotherapy for AML
NCT04977180Phase 2Recruiting
- Sponsor
- University of Virginia
- Start
- Mar 2022
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of metoprolol, carvedilol and lisinopril in Cardiotoxicity (2 arms), sponsored by University of Virginia. Primary endpoint: Left ventricular ejection fraction at 6 months. Started Mar 2022; status: recruiting.
02
Drugs
metoprololcarvedilollisinopril
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT04977180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04977180.